For: | Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v25/i41/6172.htm |
Number | Citing Articles |
1 |
Parambir S. Dulai, Brian G. Feagan, Bruce E. Sands, Jingjing Chen, Karen Lasch, Richard A. Lirio. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2023; 21(2): 456 doi: 10.1016/j.cgh.2022.07.027
|
2 |
Alexandre Loktionov. Colon mucus in colorectal neoplasia and beyond. World Journal of Gastroenterology 2022; 28(32): 4475-4492 doi: 10.3748/wjg.v28.i32.4475
Abstract(111) |
Core Tip(120) |
Full Article(HTML)(1064)
|
Full Article (PDF)-3098K(177)
|
Full Article (Word)-2076K(31)
|
Audio-1255K(1)
|
Peer-Review Report-191K(26)
|
Answering Reviewers-91K(25)
|
Times Cited (0)
|
Total Visits (2199)
|
Open
|
3 |
Cambrian Y. Liu, Candace M. Cham, Eugene B. Chang. Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier. Translational Research 2021; 236: 35 doi: 10.1016/j.trsl.2021.06.001
|
4 |
J.K. Yamamoto-Furusho, N.N. Parra-Holguín. Real-world experience with MMX mesalazine use in Mexican patients with ulcerative colitis at two tertiary care centers. Revista de Gastroenterología de México (English Edition) 2022; 87(3): 305 doi: 10.1016/j.rgmxen.2021.06.002
|
5 |
Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon. Long‐term clinical outcomes of intestinal Behçet's disease: A 30‐year cohort study at a tertiary hospital in South Korea. Journal of Gastroenterology and Hepatology 2022; doi: 10.1111/jgh.16056
|
6 |
Dimitri Poddighe, Aigerim Telman, Ernas Tuleutayev, Aigul Ibrayeva. Pediatric Ulcerative Colitis in Kazakhstan: First Case Series from Central Asia and Current Clinical Management. Gastroenterology Insights 2020; 11(2): 27 doi: 10.3390/gastroent11020006
|
7 |
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay, Patricio Ibañez. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021; 44(4): 312 doi: 10.1016/j.gastre.2020.06.023
|
8 |
Dora Grgić, Karlo Golubić, Marko Brinar, Željko Krznarić. Predictive value of faecal calprotectin in ulcerative colitis – single centre experience. Annals of Medicine 2022; 54(1): 1570 doi: 10.1080/07853890.2022.2082518
|
9 |
Antonio Facciorusso, Daryl Ramai, Cristina Ricciardelli, Rosa Paolillo, Marcello Maida, Saurabh Chandan, Babu P. Mohan, Viktor Domislovic, Rodolfo Sacco. Prognostic Role of Post-Induction Fecal Calprotectin Levels in Patients with Inflammatory Bowel Disease Treated with Biological Therapies. Biomedicines 2022; 10(9): 2305 doi: 10.3390/biomedicines10092305
|
10 |
Kanya K Shah, Aisling R Caffrey, Andy Szczotka, Dea Belazi, Stephen J Kogut. Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease. Journal of Managed Care & Specialty Pharmacy 2022; 28(8): 849 doi: 10.18553/jmcp.2022.28.8.849
|
11 |
José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset. Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests. Intestinal Research 2022; 20(3): 361 doi: 10.5217/ir.2021.00126
|
12 |
D.C.R. Fernandes, H.J.N. Andreyev. Gastrointestinal Toxicity of Pelvic Radiotherapy: Are We Letting Women Down?. Clinical Oncology 2021; 33(9): 591 doi: 10.1016/j.clon.2021.04.009
|
13 |
Vito Annese, Peter L. Lakatos. A further “stri(v)de” in IBD management. Digestive and Liver Disease 2020; 52(7): 721 doi: 10.1016/j.dld.2020.02.005
|
14 |
J.K. Yamamoto-Furusho, N.N. Parra-Holguín. Experiencia de la vida real con el uso de mesalazina MMX en pacientes mexicanos con CUCI en dos centros de tercer nivel. Revista de Gastroenterología de México 2022; 87(3): 305 doi: 10.1016/j.rgmx.2021.01.010
|
15 |
JiuJie Yang, Jerome P.L. Ng, Kaixi Zhang, Liang Liu, Vincent Kam Wai Wong. Rheumatoid Arthritis. 2022; doi: 10.5772/intechopen.99212
|
16 |
David Fenton, Natalie K Choi, Nicole M Garcia, Emma C Dyer, Nathaniel A Cohen, David T Rubin. Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project. Crohn's & Colitis 360 2022; 4(4) doi: 10.1093/crocol/otac042
|
17 |
Ferdinando D’Amico, Thomas Chateau, Valérie Laurent, Silvio Danese, Laurent Peyrin-Biroulet. Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?. Journal of Clinical Medicine 2020; 9(6): 1691 doi: 10.3390/jcm9061691
|
18 |
Vilk Janne da Silva Barros, Juliana Soares Severo, Pedro Henrique Moraes Mendes, Alda Cássia Alves da Silva, Kelly Beatriz Vieira de Oliveira, José Miguel Luz Parente, Murilo Moura Lima, Emídio Marques Matos Neto, Armênio Aguiar dos Santos, Moisés Tolentino. Effect of dietary interventions on inflammatory biomarkers of inflammatory bowel diseases: A systematic review of clinical trials. Nutrition 2021; : 111457 doi: 10.1016/j.nut.2021.111457
|
19 |
Laurent Peyrin-Biroulet, William J. Sandborn, Remo Panaccione, Eugeni Domènech, Lieven Pouillon, Britta Siegmund, Silvio Danese, Subrata Ghosh. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therapeutic Advances in Gastroenterology 2021; 14: 175628482110599 doi: 10.1177/17562848211059954
|
20 |
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay, Patricio Ibañez. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología 2021; 44(4): 312 doi: 10.1016/j.gastrohep.2020.06.032
|